The Risk of Autoimmune Disorders in Treated Celiac Disease Patients in Olmsted County, Minnesota.
Journal
Journal of pediatric gastroenterology and nutrition
ISSN: 1536-4801
Titre abrégé: J Pediatr Gastroenterol Nutr
Pays: United States
ID NLM: 8211545
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
pubmed:
21
6
2019
medline:
2
10
2020
entrez:
21
6
2019
Statut:
ppublish
Résumé
Patients with autoimmune disorders (ADs) are at increased risk for celiac disease (CD), but data are conflicting on the risk of ADs in treated patients with CD. We aimed to assess the incidence of ADs in treated patients with CD. Using the Rochester Epidemiology Project, we retrospectively searched for the medical records at Mayo Clinic and Olmsted Medical Center from January 1997 to December 2015 for patients with CD who met accepted diagnostic criteria. For each patient with CD, we identified 2 age and sex-matched controls during the same study period. The incidence rate of AD diagnosis 5 years after index date was calculated using Kaplan-Meier analysis for the CD cases and controls and compared using the log-rank test. We identified 249 treated patients with CD during the study period and 498 matched controls, with mean (standard deviation) ages of 32 (22) years and 33 (22) years, respectively. One third of patients (n = 85) and controls (n = 170) were boys. Five years after the index date, 5.0% of patients with CD and 1.3% of controls had a de novo AD diagnosis (P = 0.006). In the presence of a prior AD, the cumulative risk of a de novo or additional AD was significantly higher in the CD group compared with controls (P < 0.001). Children had a significantly higher risk of AD development compared with adults (P = 0.010). Treated patients with CD are at higher risk for the development of ADs. The risk of a new AD is higher in children, especially when >1 AD diagnosis exists.
Sections du résumé
BACKGROUND
Patients with autoimmune disorders (ADs) are at increased risk for celiac disease (CD), but data are conflicting on the risk of ADs in treated patients with CD. We aimed to assess the incidence of ADs in treated patients with CD.
METHODS
Using the Rochester Epidemiology Project, we retrospectively searched for the medical records at Mayo Clinic and Olmsted Medical Center from January 1997 to December 2015 for patients with CD who met accepted diagnostic criteria. For each patient with CD, we identified 2 age and sex-matched controls during the same study period. The incidence rate of AD diagnosis 5 years after index date was calculated using Kaplan-Meier analysis for the CD cases and controls and compared using the log-rank test.
RESULTS
We identified 249 treated patients with CD during the study period and 498 matched controls, with mean (standard deviation) ages of 32 (22) years and 33 (22) years, respectively. One third of patients (n = 85) and controls (n = 170) were boys. Five years after the index date, 5.0% of patients with CD and 1.3% of controls had a de novo AD diagnosis (P = 0.006). In the presence of a prior AD, the cumulative risk of a de novo or additional AD was significantly higher in the CD group compared with controls (P < 0.001). Children had a significantly higher risk of AD development compared with adults (P = 0.010).
CONCLUSIONS
Treated patients with CD are at higher risk for the development of ADs. The risk of a new AD is higher in children, especially when >1 AD diagnosis exists.
Identifiants
pubmed: 31219935
doi: 10.1097/MPG.0000000000002418
pmc: PMC6768731
mid: NIHMS1530696
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
438-442Subventions
Organisme : NIA NIH HHS
ID : R01 AG034676
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR030582
Pays : United States
Références
Gastroenterology. 1999 Aug;117(2):297-303
pubmed: 10419909
J Pediatr. 2000 Jan;136(1):86-90
pubmed: 10636980
J Pediatr. 2000 Aug;137(2):263-5
pubmed: 10931424
Gut. 2001 Oct;49(4):502-5
pubmed: 11559646
Arch Intern Med. 2003 Feb 10;163(3):286-92
pubmed: 12578508
J Pediatr Gastroenterol Nutr. 2003 Jul;37(1):63-6
pubmed: 12827007
Clin Gastroenterol Hepatol. 2003 Jan;1(1):19-27
pubmed: 15017513
Clin Gastroenterol Hepatol. 2004 Feb;2(2):107-12
pubmed: 15017614
Gastroenterology. 2005 Apr;128(4 Suppl 1):S68-73
pubmed: 15825129
Scand J Gastroenterol. 2005 Apr;40(4):437-43
pubmed: 16028438
N Engl J Med. 2007 Oct 25;357(17):1731-43
pubmed: 17960014
Hepatology. 2007 Nov;46(5):1650-8
pubmed: 17969053
Clin Gastroenterol Hepatol. 2008 Jul;6(7):753-8
pubmed: 18255352
Adv Pediatr. 2008;55:349-65
pubmed: 19048738
J Pediatr. 2009 Jul;155(1):51-5, 55.e1
pubmed: 19324373
Gastroenterology. 2010 Sep;139(3):763-9
pubmed: 20685275
Therap Adv Gastroenterol. 2008 Nov;1(3):169-72
pubmed: 21180526
J Pediatr Gastroenterol Nutr. 2012 Jan;54(1):136-60
pubmed: 22197856
Ir J Med Sci. 2012 Jun;181(2):225-9
pubmed: 22203320
Am J Gastroenterol. 2012 Oct;107(10):1538-44; quiz 1537, 1545
pubmed: 22850429
Mayo Clin Proc. 2012 Dec;87(12):1202-13
pubmed: 23199802
Am J Gastroenterol. 2013 May;108(5):818-24
pubmed: 23511460
Am J Gastroenterol. 2013 May;108(5):656-76; quiz 677
pubmed: 23609613
Curr Allergy Asthma Rep. 2013 Aug;13(4):347-53
pubmed: 23681421
Aliment Pharmacol Ther. 2014 Nov;40(10):1123-32
pubmed: 25270960
J Pediatr Gastroenterol Nutr. 2016 Jul;63(1):156-65
pubmed: 27035374
PLoS One. 2016 Dec 28;11(12):e0168708
pubmed: 28030626
Aliment Pharmacol Ther. 2018 Mar;47(5):563-572
pubmed: 29322540
Nutrients. 2018 Jun 25;10(7):null
pubmed: 29941778
Scand J Gastroenterol. 1988 Oct;23(8):1000-4
pubmed: 3201123
Mayo Clin Proc. 1996 Mar;71(3):266-74
pubmed: 8594285